【摘要】 目的 :研究卡培他滨单药治疗复治的晚期复发性乳腺癌的近期疗效。方法 :全组 2 1例复发的晚期乳腺癌 ,卡培他滨 2 5 0 0mg/ (m2 ·d) ,分早晚两次口服 ,连服 14天 ,2 1天为 1个周期 ,治疗至少 2个周期后评价疗效及毒性反应。结果 :2 0例可评价疗效 ,全组无CR ,PR 6例 (30 .0 % ) ,SD 8例 (40 .0 % ) ,PD 6例 (30 .0 % ) ,总有效率为 30 .0 %。主要的毒性反应为手足综合征 (6 1.1% )、恶心呕吐 (6 6 .7% )、白细胞减少 (42 .9% )及皮肤色素沉着(2 3.8% )。结论 :卡培他滨对经蒽环类、紫杉类等药物治疗后复发的晚期乳腺癌仍有较好疗效 ,且毒副反应小 ,耐受性好 ,可作为复发的晚期乳腺癌的二线治疗方案。更多还原

【Abstract】 Purpose:To observe the efficacy of capecitabi ne in the treatment of relapsed breast cancer. Methods:21 patients with relapsed breast cancer were treated. C apecitabine was administered twice a day at the dose of 2 500 mg/(m 2·d) f or two weeks. 21 days was one cycle. Patients could be evaluated after at least 2 cycles treatment. Results:20 patients could be evaluated. There were no complete response but 6 partial response, 8 stable disease and 6 progressive disease in t he group. The response rate was 30.0%. The common toxic effects were hand-foot syndrome (61.1%), nausea and vomiting(66.7%), leucopenia (42.9%) and skin pigm entation (23.8%). Conclusions:Capecitabine is effective for the relapsed breast c ancer patients who have been treated with anthracycline and taxanes. The toxic e ffects are mild and the tolerance is well. Capecitabine can be used as the secon d line regimen for relapsed breast cancer.更多还原